Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| TransCode Therapeutics Inc | RNAZ | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.4399 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.4399 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.42 - 371.68 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.4399 | USD |
TransCode Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 276.07k | 627.44k | - | 0 | -18.55M | -29.56 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
TransCode Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNAZ Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.5087 | 0.52 | 0.42 | 0.4779185 | 198,192 | -0.0688 | -13.52% |
| 1 Month | 0.6789 | 0.7082 | 0.42 | 0.5512064 | 351,288 | -0.239 | -35.20% |
| 3 Months | 0.72 | 0.76 | 0.42 | 0.6408223 | 438,879 | -0.2801 | -38.90% |
| 6 Months | 15.54 | 19.424 | 0.42 | 9.39 | 2,013,045 | -15.10 | -97.17% |
| 1 Year | 264.00 | 371.68 | 0.42 | 36.54 | 2,309,552 | -263.56 | -99.83% |
| 3 Years | 4,800.00 | 5,600.00 | 0.42 | 1,012.88 | 1,707,095 | -4,799.56 | -99.99% |
| 5 Years | 4,800.00 | 5,600.00 | 0.42 | 1,012.88 | 1,707,095 | -4,799.56 | -99.99% |
TransCode Therapeutics Description
| TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. |
